<DOC>
	<DOCNO>NCT01337505</DOCNO>
	<brief_summary>This phase 1b open-label study evaluate preliminary safety maximum tolerate dose new formulation INNO-206 administer dos 230 mg/m2 , 350 mg/m2 450 mg/m2 ( 165 , 260 , 325 mg/m2 doxorubicin equivalent , respectively ) intravenous infusion Day 1 every 21 day 6 cycle .</brief_summary>
	<brief_title>Safety Maximum Tolerated Dose ( MTD ) Study INNO-206 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Age 18 70 year , male female . Histologically cytologically confirm malignant solid tumor relapse refractory standard therapy . Subjects receive prior radiation therapy stable CNS metastasis progression brain metastasis CT/MRI scan last 4 week . Capable provide informed consent comply trial procedure . ECOG performance status 02 . Life expectancy &gt; 12 week . Measurable evaluable disease accord RECIST 1.1 criterion . Women must able become pregnant ( e.g . post menopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . Geographic accessibility site . Palliative surgery , chemotherapy , immunotherapy and/or radiation le 4 week prior Screening Visit . Exposure investigational agent within 30 day Screening Visit . Laboratory value : Screening serum creatinine great equal 1.5 mg/dL , alanine aminotransferase ( ALT ) great 3 time upper limit normal , total bilirubin great 3 time upper limit normal , white blood cell ( WBC ) count &lt; 3500/mm3 , absolute neutrophil count &lt; 2000/mm3 , platelet concentration &lt; 100,000/mm3 , hematocrit level &lt; 33 % female &lt; 35 % male , coagulation test ( PT , PTT ) &gt; 1.5 time upper limit normal . Clinically evident congestive heart failure &gt; class II New York Heart Association ( NYHA ) guideline . Serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V. History sign active coronary artery disease without angina pectoris . Serious myocardial dysfunction define scintigraphically ( MUGA , myocardial scintigram ) ultrasound determine absolute leave ventricular ejection fraction ( LVEF ) &lt; 45 % predict . History HIV infection . Active , clinically significant serious infection require treatment antibiotic , antiviral antifungal . Major surgery within 3 week prior treatment . Substance abuse condition might interfere subject 's participation study evaluation study result . Any condition unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>INNO-206</keyword>
	<keyword>Phase 1</keyword>
	<keyword>DOXO-EMCH</keyword>
	<keyword>Advanced solid tumor</keyword>
</DOC>